Exploring Therapeutic Advancement and Strategies Associated with Drug Delivery in Brain-Tumor Targeting.

IF 3 4区医学 Q2 PHARMACOLOGY & PHARMACY Critical Reviews in Therapeutic Drug Carrier Systems Pub Date : 2021-01-01 DOI:10.1615/CritRevTherDrugCarrierSyst.2020033839

Bjorn John Stephen, Madan Mohan Sharma, Devendra Jain, Harshdeep Dhaliwal, Vikram Sharma, Abhijeet Singh

{"title":"Exploring Therapeutic Advancement and Strategies Associated with Drug Delivery in Brain-Tumor Targeting.","authors":"Bjorn John Stephen, Madan Mohan Sharma, Devendra Jain, Harshdeep Dhaliwal, Vikram Sharma, Abhijeet Singh","doi":"10.1615/CritRevTherDrugCarrierSyst.2020033839","DOIUrl":null,"url":null,"abstract":"<p><p>Brain tumors pose a serious burden to health care because the cancers are usually incurable, despite advancements in treatment strategies including surgery, radiotherapy, and chemotherapy. Most studies report that specific drugs are effective in vitro, but many lose their therapeutic value in clinical settings. Maintaining therapeutic drug concentrations as an agent reaches a cancer target is the efficacy prerequisite for any form of treatment. However, in the case of brain tumors, the blood-brain barrier (BBB) acts to physically and physiologically block the drug, which complicates treatment options. In addition, strategies are limited by a number of factors such as difficulties that are associated with targeting tumor cells. The therapeutic potential of targeted drug delivery as an alternative to current strategies is gaining significant ground, with many studies highlighting its efficacy and compatibility in overcoming the BBB before reaching its final target in brain. In this review, we briefly describe basic physiology associated with the BBB and how modern science is taking advantage of physiological processes to deliver anticancer agents to brain. We also summarize different modes of drug delivery and highlight how nanoparticles as drug-delivery vehicles are used for drug transport in brain tumors as well as different types of surface modification that are used to increase target potential.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical Reviews in Therapeutic Drug Carrier Systems","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2020033839","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Brain tumors pose a serious burden to health care because the cancers are usually incurable, despite advancements in treatment strategies including surgery, radiotherapy, and chemotherapy. Most studies report that specific drugs are effective in vitro, but many lose their therapeutic value in clinical settings. Maintaining therapeutic drug concentrations as an agent reaches a cancer target is the efficacy prerequisite for any form of treatment. However, in the case of brain tumors, the blood-brain barrier (BBB) acts to physically and physiologically block the drug, which complicates treatment options. In addition, strategies are limited by a number of factors such as difficulties that are associated with targeting tumor cells. The therapeutic potential of targeted drug delivery as an alternative to current strategies is gaining significant ground, with many studies highlighting its efficacy and compatibility in overcoming the BBB before reaching its final target in brain. In this review, we briefly describe basic physiology associated with the BBB and how modern science is taking advantage of physiological processes to deliver anticancer agents to brain. We also summarize different modes of drug delivery and highlight how nanoparticles as drug-delivery vehicles are used for drug transport in brain tumors as well as different types of surface modification that are used to increase target potential.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

探索脑肿瘤靶向药物递送的治疗进展和策略。

脑肿瘤对医疗保健造成了严重的负担，因为尽管手术、放疗和化疗等治疗策略取得了进展，但这种癌症通常是无法治愈的。大多数研究报告，特定的药物是有效的体外，但许多失去其治疗价值在临床设置。当药物达到癌症目标时，维持治疗药物浓度是任何形式治疗的有效性前提。然而，在脑肿瘤的情况下，血脑屏障(BBB)在生理和生理上阻断了药物，这使治疗方案复杂化。此外，策略受到许多因素的限制，例如与靶向肿瘤细胞相关的困难。靶向药物递送作为当前策略的替代治疗潜力正在取得重大进展，许多研究强调了其在到达脑内最终目标之前克服血脑屏障的功效和相容性。在这篇综述中，我们简要介绍了与血脑屏障相关的基本生理学，以及现代科学如何利用生理过程将抗癌药物输送到大脑。我们还总结了不同的药物传递模式，并强调了纳米颗粒作为药物传递载体如何用于脑肿瘤中的药物运输，以及用于增加靶标电位的不同类型的表面修饰。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Critical Reviews in Therapeutic Drug Carrier Systems 医学-药学

CiteScore

5.50

自引率

18.50%

发文量

审稿时长

>12 weeks

期刊介绍： Therapeutic uses of a variety of drug carrier systems have significant impact on the treatment and potential cure of many chronic diseases, including cancer, diabetes mellitus, psoriasis, parkinsons, Alzheimer, rheumatoid arthritis, HIV infection, infectious diseases, asthma, and drug addiction. Scientific efforts in these areas are multidisciplinary, involving the physical, biological, medical, pharmaceutical, biological materials, and engineering fields. Articles concerning this field appear in a wide variety of journals. With the vast increase in the number of articles and the tendency to fragment science, it becomes increasingly difficult to keep abreast of the literature and to sort out and evaluate the importance and reliability of the data, especially when proprietary considerations are involved. Abstracts and noncritical articles often do not provide a sufficiently reliable basis for proper assessment of a given field without the additional perusal of the original literature. This journal bridges this gap by publishing authoritative, objective, comprehensive multidisciplinary critical review papers with emphasis on formulation and delivery systems. Both invited and contributed articles are subject to peer review.